Strategies for Effective Pain Management in Clinical Practice (Module 2)
An Interactive Learning Experience
This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
The nation is facing competing public health issues: the need to treat a large number of Americans with acute and chronic pain versus the crisis of prescription opioid abuse. AMGA has partnered with Pri-Med’s Strategies for Effective Pain Management in Clinical Practice curriculum to provide education to AMGA physicians and other AMGA health care providers engaged in prescribing and or treating patients with opioid analgesics. This program is intended for those involved with direct patient care, including all members of the healthcare team.
Strategies for Effective Pain Management in Clinical Practice curriculum focuses on improving clinicians’ ability to recognize, diagnose, and classify pain; educating clinicians on the full spectrum of pain management options, including non-opioid pharmacologic interventions; and providing risk reduction strategies through integration of opioids into individualized pain management plans. Presenting clinicians with a thorough review of the FDA’s “Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain” will allow clinicians to provide evidence-based pain management to their patients on a daily basis. This curriculum will also provide tools to help clinicians mitigate issues associated with opioid therapies, recognizing the signs and symptoms of opioid dependence and abuse to best manage patients’ pain and medication use, and take steps to avert the opioid addiction crisis.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see here for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Professor of Anesthesiology and Medicine
The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
Chief, Pain Medicine and Professor of Oncology
Roswell Park Cancer Institute
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Charles E. Argoff, MD, FABPM: Advisory Board for Amgen, BioDelivery Sciences International, Inc., Clexio Biosciences, Nevro, Neumentum, Regeneron Pharmaceuticals, SK Life Sciences, Teva Pharmaceuticals, and Tremeau Pharmaceuticals, Inc., and Vertex. Consulting for EnZen Therapeutics, Opioid PMR Consortium, and XGene Pharma. Contracted Research for AbbVie, Allergan, Amgen, Lilly, Lundbeck, and Teva. Services Provided for Promotional Purposes for Collegium. Speaker’s Bureau for AbbVie, Amgen, Biohaven, Lilly, Nevro, Redhill Pharma, and Teva.
Oscar A. de Leon-Casasola, MD: Advisory Board for Esteve Pharma, Heron Therapeutics, Medtronic, Tremeau Pharma.
Katherine E. Galluzzi, DO, CMD, FACOFP: No relevant financial relationships to disclose.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.
This activity is approved for 1.20 contact hours of continuing education, which includes 0.471 hours of pharmacology.
Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 3 out of the 4 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.
Successful completion of this CME activity (“Strategies for Effective Pain Management in Clinical Practice”), which includes participation in the evaluation component, enables the participant to earn up to 3.5 Medical Knowledge & Patient Safety MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory (https://www.continuingcertification.org), Strategies for Effective Pain Management in Clinical Practice has met the requirements as a MOC Part II Self-Assessment Activity and MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
MOC Part II Self-Assessment Activity:
Physical Medicine and Rehabilitation
ABMS MOC Part II CME Activity:
Allergy and Immunology
Colon and Rectal Surgery
Psychiatry and Neurology
This activity satisfies topic-specific CME/CE requirements (pain management, controlled substances, etc.) of many state licensing boards. Please check with your state’s licensing boards for specific requirements, and print this page as appropriate for documentation.
Texas: This activity is approved for Pain Management and Prescription of Opioids requirements from the Texas Medical Board/Board of Nursing, which may also satisfy the medical ethics and/or professional responsibility.
Iowa: This activity is designed to satisfy requirements of ARNPs, for CE regarding the US Centers for Disease Control and Prevention Guideline for prescribing opioids for chronic pain. Please print this page as documentation, for submission with your CE certificate.
Kentucky: Strategies for Effective Pain Management in Clinical Practice (Modules 1, 2, 3) has been approved by KBML as meeting the statutory requirements toward HB1. ID #1121-H3.5-PM1. Learners must complete all three modules to satisfy this requirement.
Opioid Analgesic REMS Program Companies
Miller Medical Communications, LLC
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.